DK1411064T3 - Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer - Google Patents

Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer

Info

Publication number: DK1411064T3
Authority: DK; Denmark
Prior art keywords: ganglioside; tumors; diagnosis; treatment; recombinant antibodies
Prior art date: 2001-04-06

Application number

DK02759752T

Other languages

English (en)

Inventor

De Acosta Del Rio Cristi Mateo

Navarro Lourdes Tatiana Roque

Requena Alejandro Av De Lopez

Valladares Josefa A Lombardero

Original Assignee

Centro Inmunologia Molecular

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-06

Filing date

2002-04-08

Publication date

2008-03-25

2002-04-08 Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular

2008-03-25 Application granted granted Critical

2008-03-25 Publication of DK1411064T3 publication Critical patent/DK1411064T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Mycology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
General Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK02759752T 2001-04-06 2002-04-08 Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer DK1411064T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CU2001008420010084A CU23007A1 (es)	2001-04-06	2001-04-06	Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
PCT/CU2002/000003 WO2002081496A2 (es)	2001-04-06	2002-04-08	Anticuerpos recombinantes asociados a gangliósidos. su uso en el diagnóstico y tratamiento de tumores

Publications (1)

Publication Number	Publication Date
DK1411064T3 true DK1411064T3 (da)	2008-03-25

Family

ID=40291118

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK02759751T DK1384726T3 (da)	2001-04-06	2002-04-08	Immunoterapeutiske kombinationer til behandling af tumorer, der overudtrykker gangliosider
DK02759752T DK1411064T3 (da)	2001-04-06	2002-04-08	Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK02759751T DK1384726T3 (da)	2001-04-06	2002-04-08	Immunoterapeutiske kombinationer til behandling af tumorer, der overudtrykker gangliosider

Country Status (36)

Country	Link
US (3)	US20040253233A1 (da)
EP (3)	EP1384726B1 (da)
JP (2)	JP4366080B2 (da)
KR (3)	KR100863509B1 (da)
CN (3)	CN1319991C (da)
AR (2)	AR033123A1 (da)
AT (3)	ATE477279T1 (da)
AU (3)	AU2002308347B2 (da)
BG (2)	BG66304B1 (da)
BR (3)	BR0208675A (da)
CA (2)	CA2441845C (da)
CU (1)	CU23007A1 (da)
CZ (2)	CZ296276B6 (da)
DE (2)	DE60223547T2 (da)
DK (2)	DK1384726T3 (da)
EA (2)	EA006310B1 (da)
EC (2)	ECSP034787A (da)
ES (2)	ES2312610T3 (da)
HR (2)	HRP20030806B1 (da)
HU (2)	HU228106B1 (da)
IL (2)	IL158246A0 (da)
IS (2)	IS6965A (da)
MX (2)	MXPA03008739A (da)
MY (3)	MY137078A (da)
NO (2)	NO20034437L (da)
NZ (2)	NZ528599A (da)
PE (1)	PE20020972A1 (da)
PL (2)	PL208109B1 (da)
PT (2)	PT1384726E (da)
SG (1)	SG161737A1 (da)
SI (2)	SI1384726T1 (da)
SK (2)	SK287914B6 (da)
UA (3)	UA76745C2 (da)
UY (2)	UY27242A1 (da)
WO (2)	WO2002081496A2 (da)
ZA (2)	ZA200307585B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7297336B2 (en) *	2003-09-12	2007-11-20	Baxter International Inc.	Factor IXa specific antibodies displaying factor VIIIa like activity
ES2523172T3 (es) *	2005-02-04	2014-11-21	Survac Aps	Vacuna de péptido de survivina
FI20055398A0 (fi) *	2005-07-08	2005-07-08	Suomen Punainen Risti Veripalv	Menetelmä solupopulaatioiden evaluoimiseksi
NZ595386A (en) *	2005-08-11	2013-08-30	Arpi Matossian Rogers	Peptides for treatment and diagnosis of autoimmune disease
SI1915397T1 (sl)	2005-08-19	2015-05-29	Wyeth Llc	Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8
ITFI20060163A1 (it) *	2006-06-29	2006-09-28	Menarini Internat Operations Luxembourg Sa	Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio
TWI434855B (zh) *	2006-11-21	2014-04-21	Hoffmann La Roche	結合物及其在免疫分析中作為參考標準之用途
EP2255787A4 (en) *	2008-02-22	2014-08-27	Katayama Chemical Ind Co Ltd	SYNTHETIC GLYCOLIPIDE-BASED LIPOSOMES
EP2166085A1 (en)	2008-07-16	2010-03-24	Suomen Punainen Risti Veripalvelu	Divalent modified cells
TWI445716B (zh)	2008-09-12	2014-07-21	Rinat Neuroscience Corp	Ｐｃｓｋ９拮抗劑類
NZ594985A (en)	2009-03-10	2013-07-26	Biogen Idec Inc	Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies
WO2010120561A1 (en)	2009-04-01	2010-10-21	Genentech, Inc.	Anti-fcrh5 antibodies and immunoconjugates and methods of use
CU23736A1 (es) *	2009-05-04	2011-11-15	Centro Inmunologia Molecular	Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
CA2780713A1 (en) *	2009-09-03	2011-03-10	Vancouver Biotech Ltd.	Monoclonal antibodies against gonadotropin-releasing hormone receptor
WO2012096994A2 (en) *	2011-01-10	2012-07-19	Emory University	Antibodies directed against influenza
CU24070B1 (es) *	2011-12-27	2015-01-29	Ct De Inmunología Molecular	Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP2641916A1 (en) *	2012-03-23	2013-09-25	Centre National de la Recherche Scientifique (C.N.R.S)	Novel antibodies anti-sPLA2-IIA and uses thereof
KR101704893B1 (ko)	2012-06-15	2017-02-08	화이자 인코포레이티드	Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
TWI725931B (zh)	2013-06-24	2021-05-01	美商建南德克公司	抗ｆｃｒｈ５抗體
PE20210107A1 (es)	2013-12-17	2021-01-19	Genentech Inc	Anticuerpos anti-cd3 y metodos de uso
BR112016020009A2 (pt) *	2014-04-10	2017-10-17	Obi Pharma Inc	anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma
TWI715587B (zh)	2015-05-28	2021-01-11	美商安可美德藥物股份有限公司	Ｔｉｇｉｔ結合劑和彼之用途
CN107849132B (zh)	2015-06-16	2022-03-08	豪夫迈·罗氏有限公司	人源化的和亲和力成熟的针对FcRH5的抗体和使用方法
WO2018017864A2 (en) *	2016-07-20	2018-01-25	Oncomed Pharmaceuticals, Inc.	Pvrig-binding agents and uses thereof
US11230596B2 (en)	2016-11-30	2022-01-25	Mereo Biopharma 5, Inc.	Methods for treatment of cancer comprising TIGIT-binding agents
CU20170173A7 (es) *	2017-12-27	2019-11-04	Ct Inmunologia Molecular	Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2754206B2 (ja) *	1987-11-17	1998-05-20	メクト株式会社	α２→３結合を認識するモノクローナル抗体
US6051225A (en) *	1988-10-19	2000-04-18	The Dow Chemical Company	Family of high affinity, modified antibodies for cancer treatment
DE69327620T2 (de) *	1992-08-18	2000-08-03	Centro De Immunologia Molecular, Ciudad De La Habana	Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen
JPH07101999A (ja) *	1993-10-06	1995-04-18	Hagiwara Yoshihide	抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
US6063379A (en) *	1993-12-09	2000-05-16	Centro De Inmunologia Molecular	Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
CU22702A1 (es) *	1997-10-21	2001-07-31	Centro Inmunologia Molecular	Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
EP0657471B1 (en) *	1993-12-09	2001-10-24	Centro de Inmunologia Molecular	Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours
US6149921A (en) *	1993-12-29	2000-11-21	Centro De Inmunologia Molecular	Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22420A1 (es) *	1993-12-29	1996-01-31	Centro Inmunologia Molecular	Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
CU22615A1 (es) *	1994-06-30	2000-02-10	Centro Inmunologia Molecular	Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22731A1 (es) *	1998-02-05	2002-02-28	Centro Inmunologia Molecular	Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US7442776B2 (en) *	1999-10-08	2008-10-28	Young David S F	Cancerous disease modifying antibodies

2001
- 2001-04-06 CU CU2001008420010084A patent/CU23007A1/es unknown
2002
- 2002-04-05 AR ARP020101264A patent/AR033123A1/es not_active Application Discontinuation
- 2002-04-05 MY MYPI20021228A patent/MY137078A/en unknown
- 2002-04-05 MY MYPI20081190A patent/MY145703A/en unknown
- 2002-04-05 MY MYPI20021239A patent/MY157372A/en unknown
- 2002-04-05 UY UY27242A patent/UY27242A1/es not_active Application Discontinuation
- 2002-04-05 UY UY27243A patent/UY27243A1/es unknown
- 2002-04-05 AR ARP020101263A patent/AR033122A1/es unknown
- 2002-04-08 CZ CZ20032641A patent/CZ296276B6/cs not_active IP Right Cessation
- 2002-04-08 MX MXPA03008739A patent/MXPA03008739A/es active IP Right Grant
- 2002-04-08 EA EA200301098A patent/EA006310B1/ru not_active IP Right Cessation
- 2002-04-08 SK SK1226-2003A patent/SK287914B6/sk not_active IP Right Cessation
- 2002-04-08 HU HU0401355A patent/HU228106B1/hu not_active IP Right Cessation
- 2002-04-08 IL IL15824602A patent/IL158246A0/xx unknown
- 2002-04-08 AU AU2002308347A patent/AU2002308347B2/en not_active Ceased
- 2002-04-08 JP JP2002580025A patent/JP4366080B2/ja not_active Expired - Fee Related
- 2002-04-08 HR HR20030806A patent/HRP20030806B1/xx not_active IP Right Cessation
- 2002-04-08 EA EA200301097A patent/EA006936B1/ru not_active IP Right Cessation
- 2002-04-08 PL PL371937A patent/PL208109B1/pl unknown
- 2002-04-08 DE DE60223547T patent/DE60223547T2/de not_active Expired - Lifetime
- 2002-04-08 KR KR1020037012938A patent/KR100863509B1/ko not_active Expired - Fee Related
- 2002-04-08 BR BR0208675-1A patent/BR0208675A/pt not_active IP Right Cessation
- 2002-04-08 HU HU0401695A patent/HU228105B1/hu not_active IP Right Cessation
- 2002-04-08 DK DK02759751T patent/DK1384726T3/da active
- 2002-04-08 CN CNB028084330A patent/CN1319991C/zh not_active Expired - Fee Related
- 2002-04-08 PT PT02759751T patent/PT1384726E/pt unknown
- 2002-04-08 NZ NZ528599A patent/NZ528599A/en not_active IP Right Cessation
- 2002-04-08 AT AT06076643T patent/ATE477279T1/de not_active IP Right Cessation
- 2002-04-08 ES ES02759751T patent/ES2312610T3/es not_active Expired - Lifetime
- 2002-04-08 WO PCT/CU2002/000003 patent/WO2002081496A2/es not_active Ceased
- 2002-04-08 BR BRPI0208675-1A patent/BRPI0208675B1/pt unknown
- 2002-04-08 SK SK1216-2003A patent/SK287783B6/sk not_active IP Right Cessation
- 2002-04-08 BR BRPI0208676A patent/BR0208676B1/pt not_active IP Right Cessation
- 2002-04-08 CN CNB028086309A patent/CN100349920C/zh not_active Expired - Fee Related
- 2002-04-08 EP EP02759751A patent/EP1384726B1/en not_active Expired - Lifetime
- 2002-04-08 ES ES02759752T patent/ES2296986T3/es not_active Expired - Lifetime
- 2002-04-08 US US10/473,977 patent/US20040253233A1/en not_active Abandoned
- 2002-04-08 CN CN2007101021039A patent/CN101054417B/zh not_active Expired - Fee Related
- 2002-04-08 MX MXPA03008738A patent/MXPA03008738A/es not_active Application Discontinuation
- 2002-04-08 SI SI200230766T patent/SI1384726T1/sl unknown
- 2002-04-08 CA CA2441845A patent/CA2441845C/en not_active Expired - Fee Related
- 2002-04-08 JP JP2002579482A patent/JP2004528033A/ja active Pending
- 2002-04-08 EP EP02759752A patent/EP1411064B1/en not_active Expired - Lifetime
- 2002-04-08 PE PE2002000283A patent/PE20020972A1/es not_active Application Discontinuation
- 2002-04-08 AT AT02759752T patent/ATE378356T1/de active
- 2002-04-08 AU AU2002308348A patent/AU2002308348B2/en not_active Ceased
- 2002-04-08 WO PCT/CU2002/000002 patent/WO2002081661A2/es not_active Ceased
- 2002-04-08 EP EP06076643A patent/EP1798243B1/en not_active Expired - Lifetime
- 2002-04-08 AT AT02759751T patent/ATE406386T1/de active
- 2002-04-08 PL PL02371770A patent/PL371770A1/xx not_active Application Discontinuation
- 2002-04-08 CZ CZ2003-2668A patent/CZ304424B6/cs not_active IP Right Cessation
- 2002-04-08 KR KR1020037012969A patent/KR100946168B1/ko not_active Expired - Fee Related
- 2002-04-08 SI SI200230660T patent/SI1411064T1/sl unknown
- 2002-04-08 SG SG200506530-5A patent/SG161737A1/en unknown
- 2002-04-08 NZ NZ528598A patent/NZ528598A/en not_active IP Right Cessation
- 2002-04-08 DK DK02759752T patent/DK1411064T3/da active
- 2002-04-08 CA CA2443372A patent/CA2443372C/en not_active Expired - Fee Related
- 2002-04-08 DE DE60228561T patent/DE60228561D1/de not_active Expired - Lifetime
- 2002-04-08 US US10/473,978 patent/US20050069535A1/en not_active Abandoned
- 2002-04-08 PT PT02759752T patent/PT1411064E/pt unknown
- 2002-04-08 HR HR20030805A patent/HRP20030805B1/xx not_active IP Right Cessation
- 2002-08-04 UA UA2003108988A patent/UA76745C2/uk unknown
- 2002-08-04 UA UA2003108989A patent/UA75393C2/uk unknown
2003
- 2003-09-23 IS IS6965A patent/IS6965A/is unknown
- 2003-09-23 IS IS6964A patent/IS2701B/is unknown
- 2003-09-29 ZA ZA200307585A patent/ZA200307585B/en unknown
- 2003-09-30 EC EC2003004787A patent/ECSP034787A/es unknown
- 2003-09-30 EC EC2003004788A patent/ECSP034788A/es unknown
- 2003-10-01 ZA ZA2003/07679A patent/ZA200307679B/en unknown
- 2003-10-02 IL IL158246A patent/IL158246A/en not_active IP Right Cessation
- 2003-10-03 NO NO20034437A patent/NO20034437L/no not_active Application Discontinuation
- 2003-10-03 BG BG108228A patent/BG66304B1/bg unknown
- 2003-10-03 NO NO20034436A patent/NO331533B1/no not_active IP Right Cessation
- 2003-10-03 BG BG108227A patent/BG66293B1/en unknown
2005
- 2005-12-20 UA UAA200512270A patent/UA86768C2/ru unknown
2007
- 2007-10-26 AU AU2007231687A patent/AU2007231687B2/en not_active Expired - Fee Related
2008
- 2008-08-07 KR KR1020087019420A patent/KR100919617B1/ko not_active Expired - Fee Related
2009
- 2009-03-19 US US12/407,046 patent/US8758753B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DK1384726T3 (da)	2008-12-15
PE20020972A1 (es)	2003-01-02
CZ296276B6 (cs)	2006-02-15
EP1411064B1 (en)	2007-11-14
WO2002081496A2 (es)	2002-10-17
CN101054417B (zh)	2012-07-11
UY27243A1 (es)	2002-09-30
NO20034437L (no)	2003-12-02
CN101054417A (zh)	2007-10-17
CA2443372C (en)	2013-05-28
ATE477279T1 (de)	2010-08-15
KR20080080680A (ko)	2008-09-04
HRP20030806B1 (en)	2011-11-30
ECSP034787A (es)	2004-01-28
SG161737A1 (en)	2010-06-29
BR0208676A (pt)	2008-04-08
EA200301097A1 (ru)	2004-02-26
SI1384726T1 (sl)	2009-04-30
US20100297008A1 (en)	2010-11-25
ES2312610T3 (es)	2009-03-01
UA86768C2 (ru)	2009-05-25
MXPA03008738A (es)	2003-12-11
CA2441845A1 (en)	2002-10-17
AU2002308347B2 (en)	2006-09-14
KR100946168B1 (ko)	2010-03-11
HUP0401695A2 (en)	2006-08-28
HUP0401355A2 (hu)	2004-10-28
HU228105B1 (en)	2012-11-28
UY27242A1 (es)	2002-07-31
SK12162003A3 (sk)	2004-05-04
AR033122A1 (es)	2003-12-03
HU228106B1 (en)	2012-11-28
IS6964A (is)	2003-09-23
JP2004525953A (ja)	2004-08-26
DE60223547T2 (de)	2008-09-18
NZ528599A (en)	2005-03-24
EA006936B1 (ru)	2006-06-30
HK1066818A1 (en)	2005-04-01
IS6965A (is)	2003-09-23
SI1411064T1 (sl)	2008-04-30
NO20034436L (no)	2003-12-02
BG66293B1 (en)	2013-02-28
EA200301098A1 (ru)	2004-04-29
CN1507452A (zh)	2004-06-23
IL158246A (en)	2010-05-31
JP4366080B2 (ja)	2009-11-18
KR20030092048A (ko)	2003-12-03
BG108227A (bg)	2005-04-30
BR0208675A (pt)	2004-08-03
PT1411064E (pt)	2008-02-12
HK1109160A1 (en)	2008-05-30
HUP0401695A3 (en)	2012-05-29
PL371937A1 (en)	2005-07-11
SK287914B6 (sk)	2012-03-02
MXPA03008739A (es)	2003-12-11
DE60223547D1 (de)	2007-12-27
CZ304424B6 (cs)	2014-04-30
CN1535282A (zh)	2004-10-06
EP1384726B1 (en)	2008-08-27
US20040253233A1 (en)	2004-12-16
EA006310B1 (ru)	2005-10-27
HRP20030805A2 (en)	2005-08-31
US8758753B2 (en)	2014-06-24
CA2443372A1 (en)	2002-10-17
BRPI0208675B1 (pt)	2018-03-13
EP1798243A3 (en)	2007-10-17
AU2007231687A1 (en)	2007-11-22
EP1411064A2 (en)	2004-04-21
ATE378356T1 (de)	2007-11-15
CU23007A1 (es)	2004-12-17
ZA200307585B (en)	2004-09-16
JP2004528033A (ja)	2004-09-16
HK1070080A1 (zh)	2005-06-10
WO2002081661A2 (es)	2002-10-17
US20050069535A1 (en)	2005-03-31
BG66304B1 (bg)	2013-03-29
UA75393C2 (en)	2006-04-17
KR100919617B1 (ko)	2009-09-29
IS2701B (is)	2010-11-15
PL371770A1 (en)	2005-06-27
WO2002081496A3 (es)	2004-02-19
CN1319991C (zh)	2007-06-06
ZA200307679B (en)	2005-03-30
SK287783B6 (sk)	2011-09-05
NO20034436D0 (no)	2003-10-03
PL208109B1 (pl)	2011-03-31
HUP0401355A3 (en)	2012-05-29
ATE406386T1 (de)	2008-09-15
KR20030087053A (ko)	2003-11-12
MY145703A (en)	2012-03-30
AU2007231687B2 (en)	2010-09-30
MY157372A (en)	2016-06-15
CN100349920C (zh)	2007-11-21
PT1384726E (pt)	2008-12-05
MY137078A (en)	2008-12-31
SK12262003A3 (sk)	2004-08-03
UA76745C2 (uk)	2006-09-15
IL158246A0 (en)	2004-05-12
NO20034437D0 (no)	2003-10-03
DE60228561D1 (de)	2008-10-09
CA2441845C (en)	2011-06-07
CZ20032668A3 (cs)	2004-07-14
NZ528598A (en)	2005-03-24
BG108228A (bg)	2005-04-30
EP1384726A2 (en)	2004-01-28
ES2296986T3 (es)	2008-05-01
AU2002308348B2 (en)	2007-11-22
CZ20032641A3 (cs)	2004-07-14
AR033123A1 (es)	2003-12-03
WO2002081661A3 (es)	2003-01-03
BR0208676B1 (pt)	2017-11-14
KR100863509B1 (ko)	2008-10-15
HRP20030806A2 (en)	2005-08-31
ECSP034788A (es)	2004-01-28
NO331533B1 (no)	2012-01-23
EP1798243A2 (en)	2007-06-20
EP1798243B1 (en)	2010-08-11
HRP20030805B1 (en)	2011-11-30

Publication	Publication Date	Title
DK1411064T3 (da)	2008-03-25	Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer
CY2019022I1 (el)	2019-11-27	Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
EE200300485A (et)	2004-02-16	Tiohüdantoinid ja nende kasutamine diabeedi raviks
NO20041225L (no)	2004-05-25	Rekombinant anti-osteopontinantistoff og anvendelse derav
NO20020554L (no)	2002-04-08	Antistoff-molekyler med spesifisitet for human tumornekrosefaktor-alfa, og anvendelse derav
EE200300528A (et)	2004-08-16	Cripto valku blokeerivad antikehad ja nende kasutamine
DK1417175T3 (da)	2013-10-28	Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DE60124863D1 (de)	2007-01-11	Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper
EE05507B1 (et)	2012-02-15	Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
NO20033387D0 (no)	2003-07-29	Modifiserte antistoffer og fremgangsmåter for anvendelse
DK1163271T3 (da)	2008-11-10	Rekombinant IL-18 antistoffer og deres anvendelse
NO20014560D0 (no)	2001-09-19	Quinasoliner og terapautisk anvendelse derav
AU2002308348A1 (en)	2003-04-10	Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
DE60229509D1 (de)	2008-12-04	Anti-osteopontin-antikörper und dessen verwendung
DK1392292T3 (da)	2006-05-29	Pyranoindazoler og deres anvendelse til behandling af glaukom
IS7348A (is)	2004-07-08	N-pýrasínýl-fenýlsúlfónamíð og notkun þeirra til að meðhöndla flakkboðatengda sjúkdóma
IS6966A (is)	2003-09-24	Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IS6967A (is)	2003-09-24	Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
NO20040249L (no)	2004-03-18	Blodgruppeantigenfusjonspolypeptider og fremgangsmater for deres anvendelse
NO20041214L (no)	2004-06-24	Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
NO20033123D0 (no)	2003-07-08	Terapeutisk hinnedannende sammensetning og behandlingsplan derav
DK1537140T3 (da)	2013-04-15	Nukleinsyre og tilsvarende protein betegnet 161P2F10B, der er anvendelige i behandling og detektering af cancer
EP1567556A4 (en)	2006-03-22	RECOMBINANT IMMUNOTOXIN AND USE IN THE TREATMENT OF TUMORS
DK1372719T3 (da)	2013-01-21	Nukleinsyre og tilsvarende protein betegnet 125P5C8, der er anvendelig i behandling og påvisning af cancer
IS6179A (is)	2001-11-28	Einklóna mótefni sem blokkerar VLA-1 og notkun þess við meðhöndlun á bólgusjúkdómum